Citius Pharmaceuticals, Inc. develops innovative therapeutics for patients with critical diseases. The company focuses on advancing medical treatments for conditions such as infectious diseases and oncology. The company self-described as unlocking potential faster.

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

COM:CITIUSPHARMA

Citius Pharmaceuticals, Inc.

Last Close

0.17

22/11 21:00

Market Cap

25.79M

Beta: -

Volume Today

240

Avg: -

Analysis Not Available